Doxifin 200mg ingles

Doxifin 200-mg Tablets
Veterinary Use
Broad spectrum antimicrobial based on doxycycline
Formula:
Each soluble 600-mg tablet contains:
Doxycycline hyclate.223.00 mg (*)
Excipient q.s.p.600.00 mg
* Equal to 200.00 mg of doxycycline basis.
General information
Doxycycline is an antibiotic from tetracycline family, with some particularities that
differentiate it from other congenerous molecules.
It has high oral absorption (about 95%), with prolonged half-life (approximately 18 to
24 hours), therefore needing daily dosages lower than other tetracyclines. The presence
of food in the stomach does not interfere in the doxycycline absorption. It has excellent
distribution and penetration in most liquids and organic tissues. It presents the highest
liposolubility degree among all tetracyclines, which facilitates the direct penetration of
the active drug through the double lipid layer of infectious agents, even reaching some
strains resistant to other tetracyclines. It acts inhibiting the protein synthesis of sensitive
etiological agents.
Doxycycline does not accumulates significantly in the circulation of animals with
kidney failure. Thus, it constitutes the safest tetracycline in the treatment of extra-renal
infections in these animals.
Doxycycline is excreted in feces, in most part as an inactive conjugate, or maybe, as
chelate; because of this, its impact on the intestinal microflora is relatively smaller.
The tablets are soluble in liquids, aiming to facilitate the administration by oral route,
which can be as tablet or suspension.
Indications
Doxifin 200-mg Tablets is indicated for treatment of several illnesses that affect dogs
and cats, caused by the following etiological agents sensitive to doxycycline:
For dogs:
Respiratory infections: (Staphylococcus spp, Streptococcus spp, Haemophilus spp,
Mycoplasma spp)
Urinary infections: (Staphylococcus spp, Streptococcus spp, Escherichia coli)
Anaplasmosis: (Anaplasma spp)
Canine erhlichiosis: (Ehrlichia canis)
Leptospirosis: (Leptospira spp)
Pododermatitis: (Fusobacterium spp, Staphylococcus spp)
Diarrheas and gastroenteritides: (Escherichia coli, Salmonella spp)
Tetanus: (Clostridium tetani)
Otitis: (Staphylococcus spp, Streptococcus spp, Pasteurella multocida)
Infected wounds and post-operatory: (Staphylococcus spp, Streptococcus spp,
Corynebacterium spp, Escherichia coli, Pasteurella multocida)
For cats:
Respiratory infections (Staphylococcus spp, Streptococcus spp, Haemophilus spp,
Mycoplasma spp)
Urinary infections: (Staphylococcus spp, Streptococcus spp, Escherichia coli)
Leptospirosis: (Leptospira spp)
Pododermatitis: (Fusobacterium spp, Staphylococcus spp)
Diarrheas and gastroenteritides: (Escherichia coli, Salmonella spp)
Tetanus: (Clostridium tetani)
Otitis: (Staphylococcus spp, Streptococcus spp, Pasteurella multocida)
Infected wounds and post-operatory: (Staphylococcus spp, Streptococcus spp,
Corynebacterium spp, Escherichia coli, Pasteurella multocida)
Mode of use and dosage
Doxifin 200-mg Tablets must be administered by oral route, in the dosage:
Doxifin Tablets
Bodyweight
one 200-mg tablet

that is, 5 mg of doxycycline per kg weight, administered at every 12 hours, during 7
consecutive days or at the veterinarian’s discretion.
The tablets can be administered together with food or dissolved in liquid.
We recommend the continuation of a treatment for up to 48 hours after the clinical
condition disappearance.
Precautions
Comply with dosages indicated for using the product.
Only the veterinarian is able to do changes in the recommended dosage for using the
product.
If there is kidney dysfunction, the dose must be reduced in order to prevent excessive
systemic accumulation.
Contraindications and use limitations
Do not administer to pregnant females.
Do not administer to animals that are less than 30 days old.
Do not administer the product with expired validity term.
Drug interactions
Do not administer to animals that are receiving treatment with barbiturates or phenytoin.
Doxycycline absorption can be affected in presence of aluminum hydroxide, sodium
bicarbonate, calcium and magnesium salts, and iron preparations.
Do not administer together to antacids.
The interaction with calcium salts can inhibit bone growth and tooth development.
Adverse effects
A prolonged treatment can cause gastrointestinal disorders, such as nausea, vomiting,
and diarrhea, which can be minimized by the administration of the product jointly with
food. The presence of food in the stomach does not compromise doxycycline
absorption.
Due to ability that doxycycline has of binding itself to calcium, it can cause heart
arrhythmias.
Keep in dry and fresh place, protected from sunlight (between 15oC and 30oC), out of
reach of children and domestic animals.
Sale under prescription and administration under veterinary orientation.
Licensed at the Ministry of Agriculture under no. 8862, on 05/07/04.
Technical Responsible: Dr. Fausto Eduardo Fonseca Terra.
CRMV/SP 10300
Validity term: 02 (two) years after the manufacturing date.
Presentation
Cartridge containing one blister with 14 tablets; cartridge containing 3 blisters with 14
tablets; and display containing 5 blisters with 14 tablets.
OURO FINO pet
Animal welfare
100% Brazilian, exporter, generating jobs in Brazil.

Owner:
Ouro Fino Saúde Animal Ltda.
Rod. Anhangüera SP 330 KM 298
CEP: 14140-000 - Cravinhos - SP
CNPJ: 57.624.462/0001-05
Phone/Fax: (16) 3518-2000
www.ourofino.com
Made in Brazil
Manufacturer:
Almapal S.A
Av, Eng. Heitor Antônio Eiras Garcia, 2756
Jardim Maria Luiza, São Paulo-SP
CEP: 05564-000
CNPJ: 48.344.725/0001-23
50120189/0507 OF21

Source: http://static.ourofino.com/files/products/download/c45b7517b72da78bdef448cb0b92e9da.pdf

Statistical brief #60: top 10 outpatient prescription medicines ranked by utilization and expenditures for the u.s. community population, 2002

Agency for Healthcare Medical Expenditure Panel Survey Research and Quality December 2004 Top 10 Outpatient Prescription Highlights Medicines Ranked by Utilization and Expenditures for the U.S. Community medicines reported as pur­chased by respondents in the Population, 2002 U.S. community population totaled $150.6 billion in 2002, an increase of 12.3 per

iranep.org

T h e n e w e ng l a n d j o u r na l o f m e dic i n e Rosiglitazone and Cardiovascular Risk Bruce M. Psaty, M.D., Ph.D., and Curt D. Furberg, M.D., Ph.D. In this issue of the Journal, Nissen and Wolski1 control groups. Across the trials, there was no report the results of a meta-analysis of treatment standard method for identifying or validating trials of rosiglitazone, as compared

Copyright © 2010 Medicament Inoculation Pdf